Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

RVC study offers hope for osteoporosis sufferers
An estimated 500,000 people are hospitalised every year for fractures owing to osteoporosis.
Researchers present NaQuinate treatment found to prevent bone loss.

Researchers at the Royal Veterinary College (RVC) have highlighted a promising new treatment for people living with skeletal disorders.

Scientists say the treatment - NaQuinate - presented today (11 September) at the American Society of Bone and Mineral Research (ASBMR), could be used to manage osteoporosis, a debilitating condition that affects more than three million people in the UK.

NaQuinate is a naturally occurring metabolite of vitamin K. Previous studies have shown that it can protect against the loss in bone quality that occurs in ovariectomy in mouse and rat models.

In this new study, NaQuinate was also shown to significantly synergise with mechanical loading in targeted regions of cortical bone. The treatment is currently in Phase I clinical trials to establish its safety and efficacy as a treatment for post-menopausal women with osteoporosis.

Professor Andrew Pitsillides, Professor of Skeletal Dynamics at the RVC, said: “There are three main ways to maintain bone quality and strength to resist fracture: stop bone loss, build mass and enhance the topographical changes to optimise and enhance weight-bearing roles. It may be that NaQuinate can achieve a balance of all three to treat osteoporosis and better maintain healthy ageing.”

An estimated 500,000 people are hospitalised every year for broken bones owing to osteoporosis. The condition causes a significant social and economic burden, with breaks often leading to a downward spiral of disability, loss of independence and increased mortality.

Prof Pitsillides added: “At the RVC we recognise the importance of a collaborative ‘One Health’ approach which operates at the cutting edge of veterinary and human medicine, and this research could pave the way for a novel treatment for this common and debilitating condition.”

The study was developed in collaboration between the Skeletal Biology group at the RVC and biotechnology company Haoma Medica.

Become a member or log in to add this story to your CPD history

Tickets on sale for horse welfare conference

News Story 1
 Tickets are now on sale for the 'Welfare and Performance of the Ridden Horse' conference, due to take place at Nottingham University on Saturday, 11 December 2021.

World-renowned researchers, including Prof. Hilary Clayton and Dr Sue Dyson, will deliver the latest research updates. There will also be interactive Q&A sessions throughout the day, interactive polls and a fun evening of entertainment.

Organisers say that in the event of further coronavirus restrictions, day tickets will be transferred to livestream tickets. For more information about the conference and to book your place, click here.  

Click here for more...
News Shorts
More cases of African swine fever confirmed in Germany

More cases of African swine fever (ASF) have been confirmed in wild boar in Germany.

According to Pig World, 20 outbreaks have been identified in two districts - Brandenburg, where the original case confirmed on September 10 was found, and near the town of Neuzelle, some 7.5 km away.

The finding represents a further seven cases confirmed by Germany's Friedrich-Loeffler Institute. A Central Crisis Team has been established to coordinate the response to the outbreak.